What We're Working On

The STAR Study Logo
Sydnexis has fully enrolled the STAR Study, its single pivotal Phase 3 study to treat the progression of myopia in children. The STAR Study is a multi-center, randomized, double masked, placebo-controlled trial evaluating two dosage strengths of SYD-101 in more than 850 children between the ages of 3-14. To learn more about the STAR Study, please visit the ClinicalTrials.gov website.
The Sydnexis STAR Study pipeline: SYD-101The Sydnexis STAR Study pipeline: SYD-101
Content TBD
Sydnexis may use and disclose online usage data about you collected automatically through online tracking technologies such as cookies, pixels, and web beacons (collectively, "cookies"). We use this data for multiple purposes, including for online targeted advertising (advertisements based on your interests inferred from your activity across other unaffiliated sites and services) and website analytics purposes, as well as to personalize content, save your preferences, provide social media features, and track the site’s performance, as further described in the "Cookies and similar tracking and data collection technologies" section of our Privacy Notice. We retain this data for as long as necessary to fulfill these purposes or as needed to comply with our record retention obligations. We do not sell your data, but we may disclose it to our marketing and advertising partners for purposes of online targeted advertising or for website analytics purposes. To opt out of the use or disclosure of your cookie-based personal data for online targeted advertising or for website analytics purposes, or to otherwise manage your preferences, please click on Cookie Settings below. For additional information on the categories of data we collect, the purposes for their collection, disclosures to third parties, and data retention, please visit our Privacy Notice.